Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 194

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Management of Atrial Fibrillation and Venous Thromboembolism: A Systematic Review

Adam, Soheir S., McDuffie, Jennifer R., Ortel, Thomas L., Williams, John W. · 2012 · Annals of Internal Medicine

Abstract

BACKGROUND: New oral anticoagulants (NOACs), including direct thrombin inhibitors (DTIs) and factor Xa (FXa) inhibitors, are emerging alternatives for prophylaxis and treatment of atrial fibrillation (AF) and venous thromboembolism (VTE). PURPOSE: To compare the benefits and harms of NOACs versus warfarin for AF and VTE. DATA SOURCES: MEDLINE, EMBASE, and the Cochrane Database of Systematic Reviews from January 2001 through July 2012; U.S. Food and Drug Administration (FDA) database for adverse event reports. STUDY SELECTION: English-language, randomized, controlled trials (RCTs) comparing NOACs with warfarin for management of AF or VTE and observational studies and FDA reports on adverse effects. DATA EXTRACTION: Two independent reviewers abstracted data and rated study quality and strength of evidence. DATA SYNTHESIS: Six good-quality RCTs compared NOACs (2 DTI studies, 4 FXa inhibitor studies) with warfarin. In AF, NOACs decreased all-cause mortality (risk ratio [RR], 0.88 [95% CI, 0.82 to 0.96]); in VTE, NOACs did not differ for mortality or VTE outcomes. Across indications, adverse effects of NOACs compared with warfarin were fatal bleeding (RR, 0.60 [CI, 0.46 to 0.77]), major bleeding (RR, 0.80 [CI, 0.63 to 1.01]), gastrointestinal bleeding (RR, 1.30 [CI, 0.97 to 1.73]), and discontinuation due to adverse events (RR, 1.23 [CI, 1.05 to 1.44]). Subgroup analyses suggest a higher risk for myocardial infarction with DTIs than with FXa inhibitors. Bleeding risk for NOACs may be increased in persons older than 75 years or those receiving warfarin who have good control. LIMITATION: There were no head-to-head comparisons of NOACs and limited data on harms. CONCLUSION: New oral anticoagulants are a viable option for patients receiving long-term anticoagulation. Treatment benefits compared with warfarin are small and vary depending on the control achieved by warfarin treatment. PRIMARY FUNDING SOURCE: Department of Veterans Affairs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/0003-4819-157-10-201211200-00532

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 53

  1. 10.1001/archinte.167.13.1414 · DOI · Paper page
  2. 10.1001/archinte.1994.00420130036007 · DOI · Paper page
  3. 10.1378/chest.119.1_suppl.220S · DOI · Paper page
  4. 10.1161/01.CIR.89.2.635 · DOI · Paper page
  5. 10.1093/oxfordjournals.eurheartj.a060739 · DOI · Paper page
  6. 1998, Lancet, 351, 233, 10.1016/S0140-6736(97)11475-1 · DOI · Paper page
  7. 10.5694/j.1326-5377.2004.tb06407.x · DOI · Paper page
  8. 10.1016/j.amjmed.2011.01.016 · DOI
  9. 10.1378/chest.08-0670 · DOI · Paper page
  10. 10.1007/s11239-008-0211-4 · doi:10.1007/s11239-008-0211-4
  11. 10.1136/hrt.2004.042465 · DOI · Paper page
  12. 10.1111/j.1742-1241.2010.02351.x · DOI
  13. 10.1146/annurev-pharmtox-010611-134633 · DOI
  14. 10.1161/CIRCULATIONAHA.111.030148 · DOI
  15. 10.1016/S1474-4422(10)70275-1 · doi:10.1016/s1474-4422(10)70275-1
  16. 10.1161/CIRCULATIONAHA.109.853119 · DOI · Paper page
  17. 10.1093/eurheartj/sun040 · doi:10.1093/eurheartj/sun040
  18. 10.1001/archinte.166.12.1269 · DOI
  19. Akl EA, 2008, Cochrane Database Syst Rev, CD006650
  20. 10.1111/j.1538-7836.2007.02847.x · DOI
  21. 10.1016/j.amjmed.2010.01.031 · DOI
  22. 10.1001/archinternmed.2011.1666 · DOI · Paper page
  23. 10.1016/0197-2456(86)90046-2 · DOI · Paper page
  24. 10.1002/sim.1186 · DOI · Paper page
  25. 10.1378/chest.11-2290 · DOI · Paper page
  26. 10.1056/NEJMoa0906598 · DOI · Paper page
  27. 10.1016/S1474-4422(10)70274-X · DOI · Paper page
  28. 10.1016/S0140-6736(10)61194-4 · DOI · Paper page
  29. 10.1161/CIRCULATIONAHA.111.055970 · DOI · Paper page
  30. 10.7326/0003-4819-155-10-201111150-00004 · DOI · Paper page
  31. 10.1159/000334578 · DOI
  32. 10.1001/archinternmed.2011.314 · DOI · Paper page
  33. Moore CH, 2011, Am J Emerg Med
  34. 10.1002/j.1875-9114.2012.01036.x · DOI
  35. Fellows SE, 2012, J Emerg Med
  36. 10.3109/15563650.2012.705290 · DOI
  37. 10.1159/000319886 · DOI
  38. 10.1160/TH11-01-0042 · DOI
  39. 10.1056/NEJMoa0905561 · DOI · Paper page
  40. 10.1016/j.amjcard.2007.06.034 · DOI · Paper page
  41. 10.1093/eurheartj/ehr113 · DOI · Paper page
  42. 10.1111/j.1538-7836.2007.02748.x · DOI · Paper page
  43. 10.1016/S0140-6736(07)61445-7 · DOI · Paper page
  44. 10.1160/TH10-10-0679 · DOI · Paper page
  45. 10.1016/j.amjcard.2012.03.049 · DOI · Paper page
  46. 10.1345/aph.1P644 · DOI
  47. 10.1177/0003319711422808 · DOI
  48. 10.1161/CIR.0b013e31820f14c0 · DOI · Paper page
  49. Wallentin L, 2010, Circulation, 120, 2158
  50. 10.4330/wjc.v3.i11.351 · DOI
  51. 10.1161/CIRCULATIONAHA.110.985655 · DOI · Paper page
  52. 10.1161/CIRCOUTCOMES.111.960591 · DOI
  53. 10.1136/bmj.b1147 · DOI · Paper page

Cited by

See all 194

Metadata

Authors
Adam, S. S., McDuffie, J. R., Ortel, T. L., & Williams, J. W.
Venue
Annals of Internal Medicine
Published
2012-12-04
Volume
157
Issue
11
Pages
796-807
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2095151586
Cited by
194
References
10
FWCI
17.07
Type
journal article
Language
en
Open access
closed
Licence
www.acpjournals.org/journal/aim/text-and-data-mining (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Management of Atrial Fibrillation and Venous Thromboembolism: A Systematic Review. https://app.cochat.ai/papers/10.7326/0003-4819-157-10-201211200-00532
The paper
Adam, S. S., McDuffie, J. R., Ortel, T. L., & Williams, J. W. (2012). Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Management of Atrial Fibrillation and Venous Thromboembolism: A Systematic Review. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-157-10-201211200-00532

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.